SRX.AX - Sirtex Medical Limited

ASX - ASX Delayed price. Currency in AUD
29.08
-0.42 (-1.42%)
At close: 4:11PM AEST
Stock chart is not supported by your current browser
Previous close29.50
Open29.49
Bid29.00 x 0
Ask29.20 x 0
Day's range28.80 - 29.49
52-week range11.06 - 30.75
Volume318,705
Avg. volume417,439
Market cap1.622B
Beta0.25
PE ratio (TTM)N/A
EPS (TTM)-0.41
Earnings dateN/A
Forward dividend & yield0.30 (1.08%)
Ex-dividend date2017-09-26
1y target est30.24
  • CDH Investments makes $1.9 billion bid for Sirtex Medical Limited (ASX:SRX)
    Motley Fool5 days ago

    CDH Investments makes $1.9 billion bid for Sirtex Medical Limited (ASX:SRX)

    Varian’s offer for Sirtex Medical Limited (ASX:SRX) at $28 a share seemed attractive, but CDH Investments raised it by 20%.

  • Australian Associated Press6 days ago

    Rival bidder confirms offer for Sirtex

    Liver cancer treatment developer Sirtex could soon be at the centre of a bidding war, as a second suitor has lodged a formal takeover offer.

  • Why these 3 ASX shares are in trading halts
    Motley Fool6 days ago

    Why these 3 ASX shares are in trading halts

    Sirtex Medical Limited (ASX:SRX) shares are one of three in trading halts today. Here's what you need to know...

  • Australian Associated Press24 days ago

    Sirtex faces $1.9b takeover counteroffer

    Australian-based liver cancer treatment developer Sirtex Medical is committing to a takeover deal with Varian, despite a higher proposal from CDH Investments.

  • Why these 3 ASX shares are in trading halts
    Motley Fool24 days ago

    Why these 3 ASX shares are in trading halts

    Sirtex Medical Limited (ASX:SRX) shares are one of three in trading halts today. Here's why...

  • Improved margins lift profit for Sirtex
    AAP3 months ago

    Improved margins lift profit for Sirtex

    Biotech Sirtex Medical, which is subject to a $1.6 billion takeover proposal from Varian Medical Systems of the US, has lifted its first-half net profit by 13 per cent and maintained its earnings guidance for the full year. The developer of an internal radiation therapy for liver cancer made a net profit of $23.5 million in the six months to December 31, with a restructure undertaken in June boosting its margins. "We are delighted with our first-half financial performance, which represents a substantial turnaround in the profitability of the business," chief executive Andrew McLean said in a statement.

  • AAP3 months ago

    Restructure helps lift Sirtex H1 profit

    Biotech Sirtex Medical has lifted its first-half net profit by 13.2 per cent to $23.5 million after a restructure undertaken in June boosted margins. However, revenue for the six months to December 31 ...

  • AAP4 months ago

    'No surprise' at huge Sirtex takeover bid

    The head of Sirtex Medical says he is not surprised US suitor Varian Medical offered a 49 per cent share price premium in its $1.6 billion takeover offer for the Australian cancer treatment developer . Sirtex CEO Andrew McLean says he was "not at all" surprised by Varian's offer, which at $28 for each Sirtex share represents a 49 per cent mark-up on the January 29 closing price of $18.83, and a 60 per cent premium to the average price over January. "Sirtex is a wonderful business with strong prospects," Mr McLean said on Wednesday.

  • AAP4 months ago

    Sirtex soars on Varian takeover offer

    Shares in liver cancer treatment developer Sirtex Medical have soared, gaining almost 50 per cent after resuming trading on Wednesday following news that US cancer care firm Varian has agreed to pay $1.6 ...

  • AAP4 months ago

    Sirtex agrees to $1.6b US takeover

    Australian-based liver cancer treatment developer Sirtex Medical has agreed to a $1.6 billion takeover offer from US company Varian. Sirtex distributes a radiation therapy to more than 1,090 hospitals in over 40 countries, and currently has a market value of $1.05 billion. Varian, which is listed on the New York Stock Exchange with a market value of $US11.8 billion, is based in California and develops radiotherapy and screening technology to treat cancer.

  • AAP4 months ago

    Sirtex shares in halt ahead of deal

    Shares in Sirtex Medical have been placed in a trading halt ahead of what the cancer treatment specialist called a "potential material corporate transaction". The liver cancer treatment developer, which booked a $26.3 million loss in 2016/17 after writedowns and failed clinical trials, this month said it expects underlying first-half earnings of $34 million - a 16 per cent improvement on the previous first half.

  • Sirtex shares jump on improved earnings
    AAP4 months ago

    Sirtex shares jump on improved earnings

    Sirtex Medical shares have surged after the liver cancer treatment specialist flagged improved first-half earnings and a turnaround in second-half sales. Sales of the company's SIR-Spheres microspheres - a product used to deliver medication to cancer sites inside the body - were flat in the first half but Sirtex CEO Andrew McLean, who took up his role in May, said the company expects higher sales in the second half of 2017/18.

  • Sirtex Q1 revenue down, but profit up
    AAP7 months ago

    Sirtex Q1 revenue down, but profit up

    Liver cancer treatments group Sirtex Medical says dosage sales in the first three months of the current financial year have been flat and sales revenue is down because of adverse currency movements, but profit is improving. Chief executive Andrew McClean has told shareholders that the first quarter is showing "some early favourable results" from the company's efforts to improve efficiency and productivity. Sirtex's main product is a medical device called SIR-Spheres Y-90 resin microspheres, to treat liver cancer.